EXOMIND (BTL-995) for Reduction of Binge-eating

Inclusion Criteria:

• Scoring more than 17 points based on the BES

• Age > 22 years

• Voluntarily signed informed consent

• Ability to determine the motor threshold of the participant. The participant's motorthreshold could be established as the minimum stimulus required to inducecontraction of the right thumb

• Subjects willing and able to abstain from partaking in any other weight managementtreatments other than the study procedure during study participation

• Willingness to comply with study instructions and to return to the clinic for therequired visits

• Women of child-bearing potential* are required to use birth control measures duringthe whole duration of the study

Exclusion Criteria:

• Electronic implants (Implanted stimulator devices in or near the head - rTMS devicesare contraindicated for use in patients who have active or inactive implants (including device leads), deep brain stimulators, cochlear implants, ocular implant,and vagus nerve stimulators, implanted devices such as cardiac pacemakers,defibrillators, neurostimulators. Contraindicated use could result in serious injuryor death.

• Metallic or other magnetic sensitive implants/objects in or near the head - rTMSdevices are contraindicated for use in patients who have conductive, ferromagneticor other magnetic-sensitive metals implanted in their head or within 30 cm of thetreatment coil. (Examples include implanted electrodes/stimulators, aneurysm clipsor coils, stents, bullet fragments, jewellery and hair barrettes. Failure to followthis restriction could result in serious injury or death.)

• Drug pump(s)

• Persons with a tendency to seizure (hypotonic, epileptic)

• Ongoing anticoagulation therapy

• Ongoing severe or life-threatening condition

• Pulmonary insufficiency

• Heart disorders

• Renal insufficiency

• Decompensated hemorrhagic conditions, blood coagulation disorders, cardiovasculardiseases

• Malignant or benign tumour

• Fever

• Facial tattoos with metallic ink (within 30 cm of the treatment coil)

• Pregnancy or nursing

• Ongoing intake disorders such as bulimia or anorexia, borderline personalitydisorder, major depression (elevated seizure risk) or bipolar disorder Personalhistory of epilepsy

• Personal history of syncope (except the reflex syncope)

• Vascular, traumatic, tumoral, infectious, or metabolic lesion of the brain, evenwithout a history of seizure, and without anticonvulsant medication

• Withdrawal from one of the following drugs could form a relative hazard for theapplication of rTMS due to the resulting significant seizure threshold loweringpotential: (e.g. alcohol, barbiturates, benzodiazepines, meprobamate, chloralhydrateetc.)

• Systemic infection

• Patients with a broad range of neuropsychiatric diseases are at elevated risk forseizures. Essentially all neurologic conditions with structural cerebral damage (e.g. stroke, multiple sclerosis, traumatic brain injury, Alzheimer's and otherneurodegenerative diseases, meningoencephalitis or intracerebral abscess,parenchymal or leptomeningeal cancers) are associated with an elevated risk forseizures

• History of hyponatremia, hypocalcemia, hypomagnesemia, hypoglycemia, hyperglycemia,renal failure/uremia, liver failure

• History of tendency for raised blood concentrations of pro-convulsant medicationsdue to reduced clearance (e.g. secondary to initiation of antibiotics for treatmentof infections)

• Immunosuppressive therapy with cyclosporine, tacrolimus and other agents that cancause the posterior reversible leukoencephalopathy syndrome

• The use of amphetamines, barbiturates, cocaine metabolites, opiates andphencyclidine 72 hours before the therapy.

• Contradictions for the testing used in the trial, for example, the motor thresholdcannot be found or quantified.